Day One Biopharmaceuticals, Inc. (DAWN) Financials
Newest figures come from the 10-K for FY2025, filed Feb 24, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the DAWN SEC filings page.
Day One Biopharmaceuticals, Inc. (DAWN) reported $158.2M in revenue for fiscal year 2025, up 20.6% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Commercial revenue is growing, but the company still converts each sales dollar into substantial cash consumption while relying on a lightly leveraged balance sheet.
From FY2024 to FY2025, revenue increased from$131.2M to$158.2M while the operating loss narrowed from$217.3M to$127.8M ; yet operating cash flow moved from-$78.1M to-$103.8M . That combination means reported earnings improved without corresponding cash-conversion improvement, an important distinction for a company still funding development.
The cost structure also changed: research and development spending fell from
The balance sheet remains lightly leveraged, with debt-to-equity at 0.2x and a current ratio of 8.0x, indicating substantial short-term asset coverage relative to obligations. Reported liquidity equaled 51 months of latest annual operating outflow, while FY2025 financing cash flow was only
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Day One Biopharmaceuticals, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Day One Biopharmaceuticals, Inc. has an operating margin of -80.8%, meaning the company loses $81 on every $100 of revenue. This results in a profitability score of 21/100. This is up from -165.7% the prior year.
Day One Biopharmaceuticals, Inc.'s revenue surged 20.6% year-over-year to $158.2M, reflecting rapid business expansion. This strong growth earns a score of 82/100.
Day One Biopharmaceuticals, Inc. carries a low D/E ratio of 0.15, meaning only $0.15 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 78/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 8.02, Day One Biopharmaceuticals, Inc. holds $8.02 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 96/100.
Day One Biopharmaceuticals, Inc.'s operations used $103.8M of cash, and capex of $320K added to the outflow, for a free cash flow shortfall of $104.1M. This results in a cash flow score of 4/100.
Day One Biopharmaceuticals, Inc. scores 18.68, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($2.2B) relative to total liabilities ($66.7M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Key Financial Metrics
Earnings & Revenue
Day One Biopharmaceuticals, Inc. generated $53.7M in revenue in Q4 2025. Against the prior quarter it is up 35.0%.
Day One Biopharmaceuticals, Inc.'s EBITDA was -$27.4M in Q4 2025, measuring earnings before interest, taxes, depreciation, and amortization. Against the prior quarter it is down 13.3%.
Day One Biopharmaceuticals, Inc. earned -$0.21 per diluted share (EPS) in Q4 2025. This represents an increase of 69.6% from the same quarter a year earlier. Against the prior quarter it is down 10.5%.
Not reported for Q4 2025.
Cash & Balance Sheet
Day One Biopharmaceuticals, Inc. recorded an outflow of $14.1M in free cash flow in Q4 2025, representing a cash shortfall after capex. This represents an increase of 55.0% from the same quarter a year earlier. Against the prior quarter it is down 143.7%.
Day One Biopharmaceuticals, Inc. held $197.1M in cash as of Q4 2025; long-term debt is not reported for that period.
Not reported for Q4 2025.
Margins & Returns
Day One Biopharmaceuticals, Inc.'s operating margin was -51.1% in Q4 2025, reflecting core business profitability. Against the prior quarter it is up 9.8 percentage points.
Not reported for Q4 2025.
Not reported for Q4 2025.
Not reported for Q4 2025.
Capital Allocation
Day One Biopharmaceuticals, Inc. invested $40.9M in research and development in Q4 2025. Against the prior quarter it is up 30.3%.
Day One Biopharmaceuticals, Inc. reported no capital expenditure in Q4 2025. This represents a decrease of 100.0% from the same quarter a year earlier.
Not reported for Q4 2025.
DAWN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $53.7M | $39.8M-57.6% | $33.9M+313.9% | $30.8M | N/A | $93.8M | $8.2M | $0 |
| R&D Expenses | $40.9M | $31.4M-6.4% | $36.1M-60.8% | $39.6M-1.5% | N/A | $33.6M+1.2% | $92.1M+186.2% | $40.2M+44.5% |
| SG&A Expenses | $34.1M | $28.1M-2.8% | $29.0M-4.0% | $29.3M+10.4% | N/A | $29.0M+58.5% | $30.2M+76.8% | $26.6M+47.3% |
| Operating Income | -$27.5M | -$24.3M-181.8% | -$35.0M+69.5% | -$41.1M+38.5% | N/A | $29.6M+157.6% | -$114.8M-133.1% | -$66.8M-45.6% |
| EBITDA | -$27.4M | -$24.2M-181.5% | -$34.9M+69.6% | -$41.0M+38.6% | N/A | $29.7M+157.7% | -$114.8M-133.1% | -$66.7M-45.6% |
| Income Tax | -$2.0M | $0+100.0% | $0-100.0% | $0 | N/A | -$882K | $1.6M | $0 |
| Net Income | N/A | -$19.7M-153.3% | -$30.3M-588.0% | -$36.0M+42.3% | N/A | $37.0M+180.3% | -$4.4M+90.4% | -$62.4M-47.2% |
| EPS (Basic) | -$0.21+69.6% | -$0.19-150.0% | -$0.29-480.0% | -$0.35+51.4% | -$0.69-7.8% | $0.38+170.4% | -$0.05+91.8% | -$0.72-22.0% |
| EPS (Diluted) | -$0.21+69.6% | -$0.19-150.0% | -$0.29-480.0% | -$0.35+51.4% | -$0.69-7.8% | $0.38+170.4% | -$0.05+91.8% | -$0.72-22.0% |
| Diluted Shares (Avg) | N/A | 103M+6.6% | 103M+18.3% | 103M+18.5% | N/A | 97M+12.8% | 87M+16.2% | 87M+20.4% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.
DAWN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $507.8M-12.9% | $513.8M-14.5% | $519.0M+29.6% | $534.4M+63.6% | $582.8M+55.0% | $600.8M+45.1% | $400.4M-11.2% | $326.6M+1.0% |
| Current Assets | $485.1M-13.7% | $490.0M-15.7% | $494.4M+29.0% | $508.7M+56.0% | $562.3M+49.8% | $581.0M+40.6% | $383.2M-14.8% | $326.0M |
| Cash & Equivalents | $197.1M+57.7% | $43.3M-89.8% | $35.6M-85.1% | $33.4M-87.7% | $125.0M-45.9% | $422.8M+75.3% | $239.6M+26.6% | $270.4M+448.8% |
| Short-Term Investments | $244.0M-40.0% | $408.3M+201.1% | $417.5M+241.5% | $439.7M+824.6% | $406.8M+200.0% | $135.6M-17.5% | $122.3M-51.8% | $47.6M-82.3% |
| Inventory | $6.3M+90.5% | $7.1M+158.2% | $6.5M+4233.1% | $3.6M | $3.3M | $2.7M | $151K | N/A |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $66.7M-16.7% | $62.9M+38.7% | $58.2M-37.9% | $54.8M+83.8% | $80.0M+171.2% | $45.3M+84.7% | $93.7M+279.3% | $29.8M+28.9% |
| Current Liabilities | $60.5M-17.6% | $56.5M+42.1% | $51.2M-45.3% | $47.9M+60.5% | $73.5M+148.9% | $39.7M+62.4% | $93.7M+282.3% | $29.8M+30.6% |
| Non-Current Liabilities | $6.1M-6.7% | $6.4M+15.1% | $7.0M | $7.0M | $6.6M | $5.6M+7171.4% | $0-100.0% | $0-100.0% |
| Total Equity | $441.2M-12.3% | $450.9M-18.8% | $460.8M+50.2% | $479.5M+61.6% | $502.8M+45.1% | $555.5M+42.6% | $306.7M-28.0% | $296.8M-1.2% |
| Retained Earnings | -$661.4M-19.4% | -$640.1M-31.1% | -$620.4M-18.1% | -$590.1M-13.3% | -$554.1M-20.8% | -$488.4M-20.9% | -$525.4M-46.8% | -$521.0M-67.0% |
Not reported in any period shown, so not listed: Accounts Receivable, Goodwill, Long-Term Debt.
DAWN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$14.1M+52.8% | -$5.8M-111.4% | -$24.8M+49.5% | -$59.0M-18.6% | -$30.0M+27.5% | $50.8M+236.9% | -$49.1M-15.8% | -$49.7M-91.4% |
| Depreciation & Amortization | $91K+139.5% | $90K+462.5% | $91K+506.7% | $94K+308.7% | $38K+192.3% | $16K+45.5% | $15K+150.0% | $23K+283.3% |
| Stock-Based Compensation | N/A | $9.6M-17.2% | $10.9M-16.4% | $12.9M+1.7% | N/A | $11.6M+20.3% | $13.0M+37.5% | $12.6M+33.8% |
| Capital Expenditures | $0-100.0% | $0-100.0% | $3K-88.5% | $317K | $1.4M+17637.5% | $724K+1665.9% | $26K-82.6% | $0-100.0% |
| Free Cash Flow | -$14.1M+55.0% | -$5.8M-111.6% | -$24.8M+49.5% | -$59.3M-19.3% | -$31.4M+24.1% | $50.0M+234.8% | -$49.2M-15.4% | -$49.7M-91.2% |
| Investing Cash Flow | $167.5M+162.1% | $13.5M+119.9% | $26.3M+54.3% | -$32.6M-136.5% | -$269.6M-987.6% | -$67.7M-176.1% | $17.1M-15.9% | $89.3M+897.7% |
| Financing Cash Flow | $471K-74.6% | $0-100.0% | $748K-42.3% | $0-100.0% | $1.9M+210.1% | $200.1M+173895.7% | $1.3M-99.2% | $48K-95.9% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
DAWN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -51.1% | -60.9%-92.5pp | -103.1% | -133.5% | N/A | 31.6% | -1401.5% | N/A |
| Net Margin | N/A | -49.6%-89.1pp | -89.4%-35.6pp | -117.0% | N/A | 39.5% | -53.8% | N/A |
| Return on Equity | N/A | -4.4%-11.0pp | -6.6%-5.1pp | -7.5%+13.5pp | N/A | 6.7%+18.5pp | -1.4%+9.3pp | -21.0%-6.9pp |
| Return on Assets | N/A | -3.8%-10.0pp | -5.8%-4.7pp | -6.7%+12.4pp | N/A | 6.2%+17.3pp | -1.1%+9.1pp | -19.1%-6.0pp |
| Current Ratio | 8.02+0.4x | 8.68-5.9x | 9.65+5.6x | 10.62-0.3x | 7.66-5.1x | 14.62-2.3x | 4.09-14.3x | 10.93 |
| Debt-to-Equity | 0.150.0x | 0.14+0.1x | 0.13-0.2x | 0.110.0x | 0.16+0.1x | 0.080.0x | 0.31+0.2x | 0.100.0x |
| Asset Turnover | 0.11 | 0.08-0.1x | 0.070.0x | 0.06+0.1x | N/A | 0.16+0.2x | 0.02 | 0.00 |
| FCF Margin | -26.3% | -14.6%-68.0pp | -73.2% | -192.8% | N/A | 53.4% | -600.0% | N/A |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Day One Biopharmaceuticals, Inc. DAWN | FY2025 | $158.2M | N/A | N/A | $2.2B | 51/100 |
| ArriVent BioPharma, Inc. AVBP | FY2025 | N/A | -$166.3M | N/A | $823.9M | — |
| Tango Therapeutics, Inc. TNGX | FY2025 | $62.4M | -$101.6M | N/A | $3.8B | 65/100 |
| Praxis Precision Medicines, Inc. PRAX | FY2025 | $0 | -$303.0M | N/A | $7.4B | — |
| Kura Oncology, Inc. KURA | FY2025 | $67.5M | -$278.7M | N/A | $935.9M | 73/100 |
| Vir Biotechnology, Inc. VIR | FY2025 | $68.6M | -$438.0M | N/A | $1.9B | 66/100 |
Where Day One Biopharmaceuticals, Inc. Ranks
Frequently Asked Questions
What is Day One Biopharmaceuticals, Inc.'s annual revenue?
Day One Biopharmaceuticals, Inc. (DAWN) reported $158.2M in total revenue for fiscal year 2025. This represents a 20.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Day One Biopharmaceuticals, Inc.'s revenue growing?
Day One Biopharmaceuticals, Inc. (DAWN) revenue grew by 20.6% year-over-year, from $131.2M to $158.2M in fiscal year 2025.
What is Day One Biopharmaceuticals, Inc.'s EBITDA?
Day One Biopharmaceuticals, Inc. (DAWN) had EBITDA of -$127.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Day One Biopharmaceuticals, Inc.'s operating margin?
Day One Biopharmaceuticals, Inc. (DAWN) had an operating margin of -80.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Day One Biopharmaceuticals, Inc.'s free cash flow?
Day One Biopharmaceuticals, Inc. (DAWN) recorded an outflow of $104.1M in free cash flow during fiscal year 2025. This represents a -29.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Day One Biopharmaceuticals, Inc.'s operating cash flow?
Day One Biopharmaceuticals, Inc. (DAWN) recorded an outflow of $103.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Day One Biopharmaceuticals, Inc.'s total assets?
Day One Biopharmaceuticals, Inc. (DAWN) had $507.8M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Day One Biopharmaceuticals, Inc.'s capital expenditures?
Day One Biopharmaceuticals, Inc. (DAWN) invested $320K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Day One Biopharmaceuticals, Inc. spend on research and development?
Day One Biopharmaceuticals, Inc. (DAWN) invested $148.1M in research and development during fiscal year 2025.
What is Day One Biopharmaceuticals, Inc.'s current ratio?
Day One Biopharmaceuticals, Inc. (DAWN) had a current ratio of 8.02 as of fiscal year 2025, which is generally considered healthy.
What is Day One Biopharmaceuticals, Inc.'s debt-to-equity ratio?
Day One Biopharmaceuticals, Inc. (DAWN) had a debt-to-equity ratio of 0.15 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
How does Day One Biopharmaceuticals, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Day One Biopharmaceuticals, Inc. (DAWN) held $441.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $103.8M over that year. Dividing the one by the other, the reported balance equals about 51 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Day One Biopharmaceuticals, Inc.'s Altman Z-Score?
Day One Biopharmaceuticals, Inc. (DAWN) has an Altman Z-Score of 18.68, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
How financially healthy is Day One Biopharmaceuticals, Inc.?
Day One Biopharmaceuticals, Inc. (DAWN) scores 51 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.